Edition:
United States

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

4.97USD
16 Jan 2019
Change (% chg)

-- (--)
Prev Close
$4.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,170
52-wk High
$11.65
52-wk Low
$3.15

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $44.39
Shares Outstanding(Mil.): 9.84
Dividend: --
Yield (%): --

Financials

  CLBS.OQ Industry Sector
P/E (TTM): 3.12 95.96 30.88
EPS (TTM): 1.44 -- --
ROI: 26.91 0.60 13.80
ROE: 28.51 -2.18 15.29

BRIEF-Roche Says Phase III Study On Alecensa Meets Primary Endpoint

* SAYS WILL TO ANNOUNCE RESULTS FROM THE PHASE III ALESIA STUDY, SHOWING THAT ALECENSA® (ALECTINIB) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED (INV) PROGRESSION-FREE SURVIVAL (PFS)

Oct 22 2018

Earnings vs. Estimates